Compare Abbott Laboratories (ABT) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while Global X NASDAQ 100 Covered Call ETF trades at $18.16. The key difference: Abbott Laboratories pays a 2.32% dividend while Global X NASDAQ 100 Covered Call ETF pays none, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | QYLD | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $18.52 |
52-Week Low | $82.57 | $16.46 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
QYLD trades at $18.18, up 0.14% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF offers a high distribution yield near 12% through covered call strategies on the Nasdaq-100, though historical data shows it has underperformed the index in strong bull markets. Recent dividends include $0.18 and $0.19 payouts in mid-2026.
Outlook is mixed: QYLD provides substantial income for risk-averse investors in sideways markets, but caps upside potential. Key risks include erosion of net asset value during rallies and competition from lower-fee alternatives. Analyst sentiment is divided, with some upgrades highlighting yield appeal amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
